Administration of Ipilimumab to a Liver Transplant Recipient With Unresectable Metastatic Melanoma
Administration of Ipilimumab to a Liver Transplant Recipient With Unresectable Metastatic Melanoma
复制标题
DOI：
10.1097/cji.0000000000000077
复制
发表时间：
2015-06-01
影响因子：
3.9
通讯作者：
Panella, Timothy J.
中科院分区：
文献类型：
--
作者：
Ranganath, Harsha A.;Panella, Timothy J.
CTLA-4免疫检查点抑制剂ipilimumab可改善转移性黑色素瘤的总生存期。其在器官移植受者中的使用尚未被研究，并且在文献中报道过一次。我们报告的情况下，一个59岁的肝移植患者谁是ipilimumab治疗晚期黑色素瘤。她没有经历器官排斥反应，免疫相关的不良事件，或肿瘤消退的证据。
The CTLA-4 immune checkpoint inhibitor ipilimumab improves overall survival in metastatic melanoma. Its use in organ transplant recipients has not been studied and has been reported once in the literature. We report the case of a 59-year-old liver transplant patient who was given ipilimumab after previous treatment for advanced melanoma. She did not experience organ rejection, immune-related adverse events, or evidence of tumor regression.